The Study to Reevaluate the Safety Efficacy of Human urinary kallikerin

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPC-15007039

Enrollment

Unknown

Registered

2015-08-25

Start date

2015-08-28

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral infarction

Interventions

Study Group:UrinaryKallidinogenase application

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Acute anterior circulation cerebral infarction diagnosed <=48h; 2. First time diagnosed or have history of acute anterior circulation cerebral infarction without serious; sequelae (mRS=0-2); 3. Age 18 to 80 years old; 4. National Institute of Health stroke scale (NIHSS) 6 to 25; 5. Have provided singed written informed consent the patient or the patients legal representative.

Exclusion criteria

Exclusion criteria: 1. Cerebal CT shows cerebal hemorrhage disease: cerebal hemorrhage, subarachnoid hemorrhage, etc.; 2. Transient ischemic attack; 3. Serious disturbance of onsciousness: Glasgow Coma ScaleGCS(GCS)<=8; 4. Combined angiotensin-converting enzyme inhibitor(ACEI) less than 5 half-time (according to its instruction), or need to be treated with ACEI; 5. Cases treated with thrombolysis / stent surgery or expectd to be treated with thrombolysis / interventional therapy / stent surgery.

Design outcomes

Primary

Measure	Time frame
Safety;	—

Secondary

Measure	Time frame
National Institute of Health stroke scale;Barthel Index;Modified Rankin Scale;	—

Countries

China

Contacts

Public ContactAnne Rong

anne.rong@techpool.com.cn+86 021-60938228

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026